The Hippo pathway in liver disease
| Project/Area Number |
25460980
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 肝癌 / Hippo pathway / 上皮間葉移行 / 接触阻害 |
|---|
| Outline of Final Research Achievements |
We discovered somatic mutations of WW45, which is a components of the Hippo pathway, in cell lines and clinical samples of liver cancer. Using one of these cell lines, We established YAP1 or TAZ knockdown cells. These transcription cofactors are downstream effector genes for this pathway. The YAP1 knocked-down cells could not grow overcoming contact inhibition. The TAZ knocked-down cells partially lost the phenotype like EMT. In YAP1 knocked-down cells, the expression of TGFB2 decresed in concordance with the expression of CTGF, an already-known target of YAP1. We are now examining the relationship between the phenotype and the expressed gene.
|
Report
(4 results)
Research Products
(1 results)
